新型两性PROTAC具有增强的药理动力学特性,用于ALK蛋白质降解
Shirui Wang1, Zhanzhan Feng1, Can Qu2
1Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.
Journal of medicinal chemistry
|June 5, 2024
概括
这项研究开发了B1-PEG,一种新型的形形蛋白解向金像体 (PROTAC),可以提高水溶性和生物可用性. 在临床前模型中,B1-PEG显示出显著的瘤回归,为向癌症治疗提供了有前途的进展.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 在抗癌策略中,蛋白质溶解向嵌合体 (PROTAC) 技术显示出前景.
- 现有的PROTACs通常具有较差的水溶性和生物可用性,限制了它们的治疗潜力.
研究的目的:
- 通过PEGylating一个优化的PROTAC分子 (B1) 来开发一种新的两性PROTAC,B1-PEG.
- 为了提高PROTACs的溶解性,生物可用性和瘤特异性药物释放.
- 在H3122异种移植小鼠模型中评估B1-PEG的体内疗效.
主要方法:
- 通过PEGylation合成B1-PEG的PROTAC分子 B1.1.
- 工程B1-PEG用于自组装成小粒,并在高GSH环境中释放.
- 进行比较B1-PEG和B1.1的药理动力学分析.
- 在H3122异种移植小鼠模型中评估瘤回归.
主要成果:
- 与未经修改的PROTAC分子B1.1.相比,B1-PEG具有显著增强的生物可用性 (84.8%).
- 在H3122异种移植小鼠模型中,B1-PEG证明了有效的瘤回归.
- 两的设计促进了菌的形成,并以瘤特定的方式触发了释放.
结论:
- 基化是一种有效的策略,可以克服PROTACs的可溶性和生物利用性差.
- 由于其改善的药理动力学特征和体内疗效,B1-PEG代表了针对性癌症治疗的有希望的候选药物.
- 这项研究为合理设计具有增强治疗功能的下一代PROTACs提供了有价值的方法.
相关概念视频
Drug Biotransformation: Overview
2.4K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.4K
Prodrugs
2.6K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
2.6K
Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.8K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.8K
Regulated Protein Degradation
7.2K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
7.2K
Phase II Reactions: Acetylation Reactions
216
Acetylation, a phase II biotransformation reaction, introduces an acetyl group to drugs or their metabolites. Acetyltransferase enzymes facilitate this reaction, which resembles α-amino acid conjugation due to the addition of a functional group to the drug molecule.
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
216
The Proteasome Structure
735
The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
The proteasome is an...
735


